



INTERNATIONAL JOURNAL OF CREATIVE RESEARCH THOUGHTS (IJCRT)

An International Open Access, Peer-reviewed, Refereed Journal

A Complete Over View on Parkinson's Disease

1Patel Swayma Siddik, 2Ms. Jadhav Pallavi T

1B Pharmacy, 2M Pharmacy

1Dbatu,

2PPCOP Wadala Mahadev, Shirrampur

Abstract:

Parkinson's sickness (PD) is the most common, insidious motor neurodegenerative disease characterized through loss of dopaminergic neurons in substantia nigra pars compacta. In historical Indian scientific device of Ayurveda, the identical disorder pathology was once documented as Kampavata, where, 'Kampa' refers to the 'shaking' or 'tremors' and 'Vata' stands for disease. This article critiques the epidemiology, History, pathophysiology, Symptoms, Treatment, Etiology and classification of Parkinson disease. The article suggests that primarily based on new research, the incidence of PD varies in distinct areas of the United States. PD impacts the international populace regardless race, clan, solid or socioeconomic barrier, with a incidence price of 0.3-0.8%. More than 1 million humans above the age of 60 years are affected through PD in USA alone. The software of glucagon-like peptide one receptor agonists, particular PD gene goal retailers (such as GBA or LRRK2 modifiers) and different possible sickness editing tablets supply cautious optimism that greater wonderful treatment plans are on the horizon. In addition to traditional motor symptoms, non-motor manifestations (such as fast eye motion sleep disorder, anosmia, constipation and depression) show up at prodromic/premotor stage and evolve, alongside with cognitive impairment and dysautonomia, as the disease progresses, frequently dominating the superior ranges of the disease. There have been no unique Recommendation involving which gene need to be examined in the medical placing for Parkinson's ailment (PD) or parkinsonism.

Factors such as symptom severity, diploma of purposeful impairment and affected person desire must be taken into account when selecting treatment. Levodopa stays the gold-standard remedy for remedy of motor signs and symptoms of Parkinson disease. Motor fluctuations and dyskinesia will improve in most sufferers 5 to ten years into the sickness whilst taking levodopa; many adjunctive oral therapies are handy to minimize motor fluctuations. The therapeutic effect as supplementary capsules to levodopa in advanced instances of PD as properly as facet impact profiles comparable to bromocriptine, however they are better tolerated with fewer g.i. symptoms.

(Keywords: Parkinson's Disease, Parkinsonism, Levodopa.)

Introduction:

Parkinson's sickness (PD) is the most established motor-neurodegenerative health problem which arises when dopaminergic neurons of substantia nigra pars compacta (SNpc) die due to pretty a wide variety endogenous or exogenous influences[1]. As a result, motor purposeful disabilities like akinesia, catalepsy, resting tremor and dyskinesia exhibit up amongst the sufferers. Cellular and molecular look up has printed that, neuronal accumulation of gap eosinophilic protein aceous aggregates specifically 'Lewy body' is the important putative contributor nearer to PD Parkinson's sickness (PD) is the most common, insidious motor neurodegenerative disease characterized through loss of dopaminergic neurons in substantia nigra pars compacta[2]. In historical Indian scientific device of Ayurveda, the identical disorder pathology was once documented as Kampavata, where, 'Kampa' refers to the 'shaking' or 'tremors' and 'Vata' stands for disease. This article critiques the epidemiology, History, pathophysiology, Symptoms, And Treatment of Parkinson disease. The article suggests that primarily based on new research, the incidence of PD varies in distinct areas of the United States. PD impacts the international populace regardless race, clan, solid or socioeconomic barrier, with a incidence price Of 0.3-0.8%. More than 1 million humans above the age of 60 years are affected through PD in USA alone[3]. The software of glucagon-like peptide one receptor agonists, particular PD gene goal retailers (such as GBA or LRRK2 modifiers) and different possible sickness editing tablets supply cautious optimism that greater wonderful treatment plans are on the horizon. In addition to traditional motor symptoms, non-motor manifestations (such as fast eye motion sleep disorder, anosmia, constipation and depression) show up at prodromic/premotor stage and evolve, alongside with cognitive impairment and dysautonomia, as the disease progresses, frequently dominating the superior ranges of the disease[4]. There have been no unique recommendations involving which genes need to be examined in the medical placing For Parkinson's ailment (PD) or parkinsonism[5]. Factors such as symptom severity, diploma of purposeful impairment and affected person desire must be taken into account when selecting treatment. Levodopa stays the gold-standard remedy for remedy of motor signs and symptoms of Parkinson disease. Motor fluctuations and dyskinesia will improve in most sufferers 5 to ten years into the sickness whilst taking levodopa; many adjunctive oral therapies are handy to minimize motor fluctuations, pathology[6]. Alpha-synuclein (α -synuclein) is the excessive constituent in Lewy body, which at once or circuitously initiates pretty a quantity cytotoxic mechanisms fundamental to the neurodegeneration [7].

Parkinson disorder is the 2d most common neurodegenerative ailment after Alzheimer 'disease[8]. Parkinson disorder normally develops between the a while of fifty five and sixty five years and happens in 1%–2% of human beings over the age of 60 years, rising to 3.5% at age 85–89 years.[9]. It impacts Primarily older adults.[10]

PD is characterized by way of the modern demise of chosen heterogeneous bundles of neurons, which consists of the Neuromelaninladen dopaminergic neurons of the SNpc[11]. Neuronal loss is determined to be more in the ventrolateral tier observed with the useful resource of the Medial ventral tier and dorsal tier inside the SNpc; however, no longer all dopamine neurons prediction is equally receptive[12]. It consequences in a regional loss of striatal dopamine, most prominently in the dorsal and intermediate

subdivisions of The put a men, a technique that is believed to account for akinesia and rigidity. Despite the terrific lookup efforts of the final Decade, the etiopathogenesis of PD is nevertheless unknown. L-dopa and DA agonists are presently used to alleviate signs of PD, then again most handled victims nevertheless increase a modern purposeful incapacity that severely influences their notable of Life [13].

Traditionally, the time duration 'idiopathic' PD has been used to describe the most normal motive of parkinsonism in clinical practice[14]. However, with the discovery of monogenic sorts of PD (which might also moreover be clinically indistinguishable from the 'idiopathic' form), the clinical heterogeneity of the sickness and the scientific overlap between PD dementia, dementia with Lewy our our bodies and exclusive sorts of parkinsonism, the nosology of PD classification needs to be constantly re-evaluated [15].

There are a quantity of danger factors viewed to be related with falls in human beings with PD[16]. These embody a archives of falls, postural instability, freezing of gait, leg muscle weakness, and cognitive impairment [17].

Neurological problems are now the main supply of incapacity in the world, and PD is the quickest developing of these disorders[18].The Global Burden of Disease Study estimates that the range of PD case will double from about 7 million in 2015 to about thirteen million in 2040, suggesting a conceivable 'PD Pandemic'[19].While this extrapolation primarily based on future boom of populace is simply an estimate, it highlights the good sized burden that PD and associated neurodegenerative stipulations can pose for society[20].

The function that genetics performs in Parkinson's disorder (PD) etiology is increasingly acknowledged. In the final few decades, we have discovered that pathogenic editions in sure genes such as LRRK2, GBA, and PRKN can be vital contributing factors. For most varieties of PD, different genetic factors, environmental sellers and growing old additionally play a position[21]. At least one foremost pathogenic variant in a PD-associated gene is recognized in about 10% of sufferers with PD, relying on the checking out used and populace studied[22] . Parkinson's disease, when inherited can be autosomal dominant, associated to editions in the genesSNCA,LRRK2, VPS35, or autosomal recessive triggered by way of variations in PRKN,PINK1[23], or PARK7 (DJ1).Variants in the GBA gene are believed to be most important threat elements for Parkinson's disease, when current in heterozygous or homozygous kingdom[24] . Other genes linked to monogenic additionally atypical types of parkinsonism have additionally been described[25] . Recently, over ninety genetic editions that show up to be related with an extended risk of PD have been recognized in genome-wide affiliation (GWAS)studies[26] . Individually, these editions are frequent in the ordinary population and are no longer related with a definable PD risk, and they are no longer usually blanketed -on commercially-available trying out panels[27].

The motives for late-onset sporadic Parkinson's the disease (PD) remain elusive, and PD is probable the cumulative result of severa genetic and environmental insults and their interactions in the context of brain aging[28]. Research on the environmental trig-triggers and modifiers for PD improvement is incredibly important for a number of reasons. First, late-on set sporadic PD takes a long time to develop, and by the time of diagnosis, neurodegenerative modifications are too advanced to decelerate, stop, or reverse .Therefore our battle in opposition to PD critically relies upon on disease early identification and intervention which in turnrely on a good grasp of disease etiology and actions upon modifiable danger factors. Second, despite recent great success in unveiling the genetic basis of late-onset sporadic PD, genetic findings may also only explain a small portion of the instances and cannot be easily prolonged to

disease prevention. On the different hand, during the decades of prodromal stage PD, many environmental elements may come into play at various time factors that may set off PD pathogenesis and modify its progression.

Adding to this potential public fitness crisis, recent evidence, albeit preliminary and inconsistent, suggests that there is an increasing style in PD incidence over the past a few decades, per chance indicating a role for environmental factors. Taken together, there is an pressing need for actions to be taken by means of funding agencies and PD researchers to perceive environmental contributions to PD development[29].

Etiology:

The relative importance of genetic and environmental/lifestyle variables in the a etiology of Parkinson's disease has been a point of contention[30]. With a median beginning age of 60 years, age is the single most important risk factor for Parkinson's disease[31]. Age-related organic failure, as well as telomere dysfunction, genomic instability, epigenetic alterations, the ubiquitin-proteasome and autophagy lysosomal system, and mitochondrial abnormalities, may support and facilitate neuronal death, as they do in other neurodegenerative illnesses[32]. Subtypes of Parkinson's disease have been proposed, with tremor-dominant and postural-instability-gait-disorder (PIGD) subtypes being the most common[33]. According to numerous studies, the PIGD phenotype is marked by more severe disorder manifestation and faster progression Different subtypes of DA receptors are different[34]. Is expressed in different parts of the brain, and appears to play Different roles. Both D1 and D2 receptors are present in Striatum and participate in therapeutic response Levodopa. They control the work of two in a row Methods with opposite effects of thalamic input in(Fig 1) [35].chrome-extension://mhjfbmdgcfjbbpaeojofohoefgiehjai/index.html.




Figure 1 Etiologies of PD: biologic interaction between genetic, epigenetic and environmental factors. PD, Parkinson's disease; REM, rapid eye movement.

Epidemiology:

It is estimated that 6.3 million human beings go through from PD worldwide. The incidence has been about to 4.5-21 instances per 100,000 populations per year. The estimates of PD incidence vary from 18 to 328 per 100,000 populations, with most research yielding a incidence of about a hundred and twenty per 100,000. The incidence and incidence of PD expanded with age. PD is about 1.5 instances greater frequent in guys than in women. The common onset age of PD is 61, however it may additionally begin as early as age forty years or even earlier than (fig. 2) [36].




Figure 2. Distribution of individuals with Parkinson's disease by country.

History:

Major milestones in PD etiopathogenesis embody the identification of intracytoplasmic inclusion our bodies ('Lewy bodies') as a pathologic hallmark via using Frederick Lewy in 1912 and the discovery of dopamine deficiency and its involvement in the parkinsonian animal fashions. The pioneering work of Arvid Carlsson and Oleh Hornykiewicz establishing in 1957 installed the hyperlink between dopamine deficiency and PD. The latter used to be as soon as supported thru the proof of concept demonstrating scientific rescue in the first trial in PD victims with intravenous levodopa in 1961 and the introduction of immoderate dosage levodopa remedy with the aid of the usage of George Cotzias in 1967 [37]. In 1982, William Langston, a neurologist, described seven victims in the San Francisco Bay Area who had been the utilization of 'synthetic heroin' and developed parkinsonian features. Subsequent investigations posted the purpose of this drug-induced parkinsonism, 1-methyl-4-phenyl-1,2,3,6-tetrahydr opyridine, which is toxic to substantia nigra dopaminergic neurons. The discovery had a extraordinarily accurate affect on look up into the etiopathogenesis of PD and experimental therapeutics, foremost to drug trials in animal fashions and large-scale epidemiological lookup on occupational publicity to viable toxins[38]. In 1996, Polymeropoulos and

colleagues determined genetic markers on chromosome 4q21-q23 to be linked to the PD phenotype in an Italian kindred and three Greek households with autosomal dominant PD, and the following 12 months they cautioned a mutation in the α -synuclein gene (SNCA), highlighting for the first time that PD would possibly additionally have a genetic etiology[39]. This landmark discovery launched an alternatively productive size of worthwhile gene hunting at some stage in which many more PD genes and genetic threat loci have been identified[40]. These findings facilitated the technology of genetic animal fashions which in end result identified new therapeutic goals for clinical trials[41].

Pathophysiology:

Parkinson disorder is a neurodegenerative syndrome involving more than one motor and nonmotor neural circuits [42]. It is characterized by means of two major pathologic processes: (a) untimely selective loss of dopamine neurons; (b) the accumulation of Lewy bodies, composed of α -synuclein, which grow to be misfolded and accumulate in multiple structures of sufferers with Parkinson disease. It is doubtful which manner happens first. Based on pathologic studies[43], there is a stepwise degeneration of neurons over many years, with every affected web page corresponding to precise symptomatology in Parkinson sickness. When motor signs turn out to be evident, there is 30–70% dopamine loss evident in the substantia nigra on pathologic examination[44]. The mainstay of remedy targets to change dopamine with dopaminergic medicines and modulate the dysfunctional circuit. Cognitive dysfunction, mood problems and impulse management problems are associated to deficits of dopamine backyard the basal ganglia or in serotonergic and noradrenergic systems[45]. Autonomic dysfunction has been associated to pathologies backyard the brain, including the spinal wire and peripheral autonomic nervous system[46].

Although we are getting to know greater every day about the pathophysiology of Parkinson's disease, it is nonetheless viewed generally idiopathic (of unknown cause). It in all likelihood includes the interplay of host susceptibility and environmental factors. A small share of instances are genetically linked and genetic elements are being intensely studied. Physiologically, the signs and symptoms related with Parkinson's disorder are the end result of the loss of a quantity of neurotransmitters, most tremendously dopamine. Symptoms aggravate over time as greater and extra of the cells affected by way of the ailment are lost. The direction of the ailment is distinctly variable, with some sufferers exhibiting very few signs as they age and others whose signs develop rapidly. Parkinson's is an increasing number of considered as a complicated neurodegenerative disorder with a sequence of progression. There is robust proof that it first impacts the dorsal motor nucleus of the vagus nerve and the olfactory bulbs and nucleus, then the locus coeruleus, and in the end the substantia nigra. Cortical areas of the brain are affected at a later stage. Damage to these a variety of neuronal structures account for the multi-faceted pathophysiologic adjustments that reason impairments now not simply to the motor device however additionally to the cognitive and neuropsychological structures (fig.3).




Figure 3:Chemical synaptic transmission.

The Pathophysiology of Parkinson's disorder is dying of dopaminergic neurons as a end result of adjustments in organic end ever in the talent with appreciate the Parkinson's ailment (PD). There are a number of proposed mechanisms for neuronal dying in PD; however, now not all of them are nicely understood. Five proposed predominant mechanisms for neuronal dying in Parkinson's Disease consist of protein aggregation in Lewy bodies, disruption of autophagy, modifications in mobile phone metabolism or mitochondrial function, neuroinflammation, and blood-brain barrier (BBB) breakdown ensuing in vascular leakiness[47].

Classification of PD:

I. Drugs affecting brain dopaminergic

system

(a) Dopamine precursor : Levodopa (l-dopa)

(b) Peripheral decarboxylase inhibitors :

Carbidopa, Benserazide.

(c) Dopaminergic agonists: Bromocriptine,

Ropinirole, Pramipexole

(d) MAO-B inhibitor: Selegiline, Rasagiline

(e) COMT inhibitors: Entacapone, Tolcapone

(f) Glutamate (NMDA receptor) antagonist


(Dopamine facilitator): Amantadine.

II. Drugs affecting brain cholinergic system

(a) Central anticholinergics: Trihexypenidyl (Benzhexol), Procyclidine, Biperiden.

(b) Antihistaminics : Orphenadrine, Promethazine.

LEVODOPA:



In Parkinson's disease, levodopa has a unique benefit: its efficacy outperforms that of any other medicine alone. It is inactive on its own, yet it is the direct cause of the problem. DA is the transmitter's predecessor. Over 95% of the time the decarboxylation of an oral dosage occurs in the tissue in the periphery (mainly gut and liver). As a result, DA produced is metabolised further, and the remainder has an effect on the heart, blood vessels, and other peripheral organs CTZ (albeit it is located in the brain) and organs it is not bound by blood, i.e. the floor of the IV ventricle. The blood-brain barrier). Approximately 1–2% of the total dose is delivered. Levodopa penetrates the blood-brain barrier and is absorbed by the dopaminergic neurons that survived were converted. DA is converted to a trans-amino acid and stored and released as a trans-amino acid. Patients with Parkinson's disease had their brains treated. DA levels were greater with levodopa till death. compared to individuals who have not been so treated. In addition, those patients Higher DA levels were found in those who had responded effectively. compared to those who responded poorly.

Actions:

1. central nervous system L-dopa not often produces any impact in regular men and girls or in sufferers with alternative neurological diseases. Marked symptomatic improvement takes place in parkinsonian patients. Hypokinesia and tension get to all-time low of 1st, later. furthermore. Secondary signs and symptoms of posture, gait, handwriting, speech, countenance, mood, self care and hobby in lifestyles area unit step by step normalized. Therapeutic gain is sort of complete in early sickness, but declines because the disease advances. The impact of L-dopa on behaviour has been described as a 'general alerting response'. In some sufferers this progresses to excitement frank psychopathy may additionally occur. Embarrassingly disproportionate expand in sexual recreation has also been noted. Dementia, if present, does not improve; as an alternative it predisposes to emergence of psychiatric symptoms. Levodopa has been accustomed manufacture a nonspecific 'awakening' impact in coma. Two subtypes of dopamine receptors (D1, D2) are originally described. 3 additional (D3, D4, D5) have currently been known and cloned. All area unit G super molecule coupled receptors and area unit grouped into 2 families: D1 like (D1, D5) area unit excitatory: act by means that of growing cAMP formation and PIP2 reaction thereby mobilizing animate thing Ca^{2+} and activating super molecule enzyme C via IP3 and DAG. D2 like (D2, D3, D4) area unit inhibitory: act by means that of inhibiting adenylyl cyclase/opening K^+ channels/depressing voltage sensitive Ca^{2+} channels. The a range of subtypes of dopamine receptors area unit differentially expressed in specific areas of the brain, and show up to play distinct roles. each D1 and D2 receptors area unit existing within the striatum and area unit troubled within the therapeutic response to levodopa. They severally regulate the exercise of 2 pathways having contrary results on the thalamic enter to the motor cortex (Fig 4).




Fig. 31.1: Simplified scheme of side loop circuits in the basal ganglia that provide modulatory input to the motor cortex. The striatal GABAergic neurons receive side-loop excitatory glutamatergic (Glu) input from the motor cortex and modulatory dopaminergic (DA) projections from the substantia nigra pars compacta (SN-PC). There are also balancing cholinergic (ACh) interneurons. The striatal neurons express both excitatory D1 and inhibitory D2 receptors. The output from the striatum to substantia nigra pars reticulata (SN-PR) and internal globus pallidus (GP-I) follows a direct and an indirect pathway. The direct pathway modulated by D1 receptors releases inhibitory transmitter GABA, while the dominant indirect pathway modulated by D2 receptors has two inhibitory (GABAergic) relays and an excitatory (glutamatergic) terminal. Due to this arrangement, dopaminergic action in the striatum exerts inhibitory influence on SN-PR and GP-I via both the pathways. The output neurons from SN-PR and GP-I feedback on the motor cortex through the thalamus using an inhibitory GABAergic link and an excitatory glutamatergic terminal. The basal ganglia modulatory loop serves to smoothen output to the spinal motor neurons and reduce basal tone.

Figure: 4

Thus, stimulation of excitative D1 as well as repressing D2 receptors within the corpus striatum achieves the same net impact of smoothening actions and decreasing muscle tone. Dopamine receptor in SN-PC and in pituitary is of D2 type. The D3 receptors predominate in nucleus accumbens and neural structure, but area unit thin in caudate and basal ganglion, while D4 and D5 area unit commonly distributed in cerebral mantle, mid brain, medulla and hippocampus.

2. CVS The peripherally intentional public prosecutor will cause arrhythmia by victimization showing on β adrenergic receptors. although public prosecutor will stimulate tube adrenergic receptors furthermore, upward jostle in BP isn't seen. Instead, orthostatic hypotension is kind of

common. this could even be a central action. Excess DA and atomic number 11 intentional within the Genius limit sympathetic outflow; to boot public prosecutor formed in involuntary ganglia will hinder ganglionic transmission. Gradual tolerance develops to every internal organ stimulant and hypotensive actions.

3. CTZ Dopaminergic receptors area unit existing in this region associated public prosecutor acts as an excitative transmitter. The public prosecutor intentional peripherally positive factors get entry to to the CTZ besides hindrance—elicits nausea and vomiting. Tolerance develops increasingly to the present action.

4. Endocrine DA acts on pituitary mammatropes to inhibit prolactin launch and on somatotropes to expand GH release. Though prolactin stages in blood fall in the course of levodopa therapy, increased GH degrees are now not referred to in parkinsonian patients. Probably the mechanisms regulating GH secretion are altered in these patients.

PHARMACOKINETICS:

Levodopa is rapidly absorbed from the small intestines by utilizing the active transport process meant for aromatic amino acids. Bioavailability of levodopa is affected by: (i) Gastric emptying: if slow, levodopa is exposed to degrading enzymes present in gut wall and liver for a longer time is available to penetrate blood-brain barrier. (ii) Amino acids present in food compete for the same carrier for absorption: blood levels are lower when taken with meals. Levodopa undergoes high first pass metabolism in g.i. mucosa and liver. The peripheral and central pathway of metabolism of levodopa is depicted.




Fig. 31.2: Metabolic pathways of levodopa in the periphery and the brain.

3-OMD—3-O-methyldopa; COMT—Catechol-O-methyl transferase; MAO—monoamine oxidase; 3-MT—3-methoxytyramine; DOPAC—3,4 dihydroxy phenylacetic acid; HVA—Homovanillic acid (3-methoxy-4-hydroxy phenylacetic acid), DDC—Dopa decarboxylase




Figure 5: Metabolic Pathway of Levodopa in Periphery and Brain.

ADVERSE EFFECTS:

Side results of dopa medical care area unit frequent and often difficult . Most area unit dose-related and limit the dose which will be administered, but are sometimes reversible. Some area unit distinguished in the beginning of medical care whereas others seem late. At the initiation of remedy These aspect effects are often reduced by beginning with an occasional dose. 1. Nausea and regurgitation It happens in nearly every patient. Tolerance step by step develops and then the dose are often steady exaggerated. 2. orthostatic hypotension It happens in regarding 1/3 of patients, however is generally asymptomatic; some patients expertise symptom, few have fainting attacks. it's larger common in patients receiving antihypertensives. Tolerance develops with continued treatment and BP normalizes. 3. Cardiac arrhythmias 4. Exacerbation of angina 5. Alteration in .

PERIPHERAL DECARBOXYIASE INHIBITORS :

Carbidopa and benserazide area unit extracerebral dopa enzyme inhibitors; they are doing not penetrate barrier and do no longer inhibit conversion of dihydroxyphenylalanine to prosecuting attorney within the brain. Administered aboard with dihydroxyphenylalanine, they increase its $t_{1/2}$ within the outer boundary and build further of it available to travel barrier and reach its computer of action. Benefits of the mixture are— 1. The plasma $t_{1/2}$ of dihydroxyphenylalanine is extended and its dose is decreased to regarding 1/4th. 2. general awareness of prosecuting attorney is reduced, nausea and instinctive reflex area unit no longer prominent— therapeutic doses of dihydroxyphenylalanine may be earned quickly. 3. viscus issues area unit decreased . 4. adermin reversal of dihydroxyphenylalanine impact will not occur.

Preparations and dose:

Carbidopa Levodopa

(per tab/cap)

TIDOMET-LS, SYNDOPA-110, 10 mg + 100 mg

SINEMET, DUODOPA-110 10 mg + 100 mg

TIDOMET PLUS, SYNDOPA PLUS 25 mg + 100 mg

TIDOMET FORTE, SYNDOPA-275 25 mg + 250 mg

BENSPAR, MADOPAR: Benserazide 25 mg + levodopa

100 mg cap

DOPAMINERGIC AGONISTS:

The DA agonists can act on striatal DA receptor seven in advanced patients who have largely lost the capacity to synthesize, store and release DA from levodopa. Moreover, they are longer acting, can exert subtype selective activation of DA receptors involved in parkinsonism and not share the concern expressed about levodopa of contributing to dopaminergic neuronal damage by oxidative metabolism. Bromocriptine. It is an ergot derivative which acts as potent agonist on D2, then again as partial agonist or antagonist on D1 receptors. Improvement in parkinsonian symptoms takes place inside $\frac{1}{2}$ –1 hr. of an oral dose of bromocriptine and lasts for 6–10 hours. If used alone, doses wished in parkinsonism are high, expensive and frequently produce insupportable side effects, particularly vomiting, hallucinations, hypotension, nasal stuffiness, conjunctival injection.



Dose: Initially 1.25 mg once at night, increase as needed up to 5 mg TDS.

PROCTINAL, SICRIPTIN, PARLODEL, 1.25, 2.5 mg tabs,

ENCRIP 2.5, 5 mg tabs.

Ropinirole and Pramipexole :

These are two nonergoline, selective D2/D3 receptor agonists with negligible affinity for D1 and nondopaminergic receptors. Pramipexole has relatively greater affinity for D3 receptors. The therapeutic effect as supplementary capsules to levodopa in advanced instances of PD as properly as facet impact profile's comparable to bromocriptine, however they are better tolerated with fewer g.i. symptoms. Consequently dose titration for most enhancement can be carried out in 1–2 weeks, whilst the equal May take countless months with bromocriptine. Ropinirole and pramipexole are now frequently used as monotherapy for early PD as well. Trials have observed them to have the funds for symptom remedy similar



to levodopa. Fewer cases treated with ropinirole wished supplement al levodopa than these dealt with bromocriptine. The Parkinson Study Group and different multicentric trials have cited decrease incidence of dyskinesias and motor fluctuations amongst patient streated with these capsules than these handled with levodopa. There is some oblique proof that use of ropinirole/pramipexole in vicinity of levodopa-carbidopa may also be related with the slow price of neuronal degeneration [48].

Pathogenesis of PD:

Cell death in the substantia nigra, specifically the ventral part of the pars compacta, is the most common pathological feature of PD, affecting up to 70% of cells by death time [49]. The loss of dopaminergic neurons in the striatum and other nuclei of the basal ganglia downstream of the striatum triggers a cascade of neurochemical changes in PD. inputs to the striatum from the substantia nigra pars compacta to the striatum (Fig.8)[50].




Figure 8: Normal basal ganglia/Physiological condition basal ganglia as compare to Basal ganglia in Parkinson's disease.

Increased inhibitory GABAergic drive from the striatum to the exterior region of Globus pallidus externa (GPe) and Globus pallidus interna (Gpi), resulting in hypoactivity of GPe and Gpi.

- GABAergic drive from the GPe to the subthalamic nucleus (STN) decreased, but glutamatergic drive increased.

This nucleus becomes hyperactive as a result of the urge to STN.

- Glutamatergic drive from the hyperactive subthalamic nucleus to the Globus pallidus interna (Gpi) and other areas of the brain. Hyperactivity is caused by the substantia nigra pars reticulata (SNpr)[51].

Both of these nuclei (Gpi/SNr) are in charge of transmitting inhibitory projections to motor nuclei located outside of the basal ganglia[52]. As a result, an inhibitory signal from Gpi/SNr is received by a motor thalamus and a brain stem locomotors region with Parkinson's illness are too inhibited (Fig.8)[53].

Symptoms:

Parkinson's disease signs and symptoms can be different for everyone. Early symptoms can also be slight and go unnoticed. Symptoms often start on one side of your physique and commonly remain worse on that side, even after signs and symptoms begin to have an impact on both sides.

Parkinson's symptoms and symptoms may additionally include:

Tremor: A tremor, or shaking, normally starts in a limb, often your hand or fingers. You might also rub your thumb and forefinger back and forth, stated as a pill-rolling tremor. Your hand may tremble when it is at rest.

Slowed movement (bradykinesia): Over time, Parkinson's disorder may additionally slow your movement, making simple tasks challenging and time-consuming. Your steps may additionally become shorter when you walk. It might also be difficult to get out of a chair. You may additionally drag your ft as you strive to walk.

Rigid muscles: Muscle stiffness may show up in any part of your body. The stiff muscle tissues can be painful and restriction your range of motion.

Impaired posture and balance: Your posture can also become stooped, or you may additionally additionally have stability problems as a end result of Parkinson's disease.

Loss of automatic movements: You can also also have a reduced ability to function unconscious movements, including blinking, smiling or swinging your fingers when you walk.

Speech changes: You can also speak softly, quickly, slur or hesitate earlier than talking. Your speech may be greater of a monotone rather than have the regular inflections.

Writing changes. It may grow to be difficult to write, and your writing might also appear small[54].

Treatment:

Treatment for Motor Symptoms:

Pharmacologic redress for Parkinson ailment motor symptom's are principally dopamine based totally[55]. Levodopa preparations', dopamine agonists, and monoamine oxidise-B (MAO-B) inhibitors are beneficial preliminary treatments[56].

For younger humans with distinguished tremor, anticholinergic agents (eg, trihexyphenidyl) are useful, however warning is required because of the attainable for destructive events, specially relating to cognition[57]. Although in the past many docs prevented levodopa for early Parkinson ailment treatment, current lookup does not support this approach[58]. One trial (PD MED) located that individuals' randomly assigned to commence therapy with levodopa (n = 528) had small however chronic mobility advantages 7 years later (1.8-point improvement [95% CI, 0.5-3.0; P = .005] in common score on the Parkinson Disease Questionnaire-39 mobility subscale[10-items; 0- to 40-point range]) in contrast with individual treated in the beginning with dopamine agonists (n = 632) or MAO-B inhibitors' (n = 460).45 Performance of ADLs was once additionally higher in the levodopa initiation team over 7 years (1.9-point improvement[95% CI, 0.7-

3.0; $P = .002$] in common rating on the Parkinson Diseases Questionnaire-39 ADL subscale [6-items, 0- to 24-point used range]). Participants in whom levodopa used to be initiated first were more probably to strengthen dyskinesias (hazard ratio, 1.52 [95% CI, 1.16-2.00]; $P = .003$), however there was once no distinction in motor fluctuations between agencies (hazard ratio, 1.11 [95% CI, 0.90-1.37]; $P = .3$). There used to be a larger possibility of discontinuing the find out about medication amongst members randomized to commence MAO-B inhibitors (72%) or dopamine agonists (50%) than amongst participants randomized to acquire levodopa (7%; $P < .001$), normally due to adverse events [59]. More than 40% of folks handled with oral dopamine agonists (ropinirole, pramipexole) trip impulse control disorders (e.g., gambling, compulsive spending, strange sexual and ingesting behavior's, compulsive remedy use, hobbyism). Individuals who discontinue use of dopamine agonists, frequently due to impulse manage disorders, ride withdrawal symptoms (eg, anxiety, panic attacks, irritability, diaphoresis, pain, drug cravings) 15% to 20% of the time [60]. Due to this, once in a while the dopamine agonist can't be discontinued no matter serious associated adverse occasions such as impulse manage disorders. Selecting the optimum approach for beginning remedy of Parkinson disorder requires shared selection making with the patient to reflect on consideration on advantages and risks. Levodopa use consequences in more purposeful enhancements however has elevated dyskinesia risks, mainly with greater doses. Severe dyskinesias are uncommon. MAO-B inhibitors and dopamine agonists are associated with much less strong symptom remedy however decrease dyskinesia risk; dopamine agonists are related with a greater ordinary threat of adverse events [61]. Ultimately, most humans with Parkinson disease use medicinal drugs from a couple of training to acquire complimentary advantages whilst limiting excessive medicine doses and dose related destructive events [62].

Over time, folks with Parkinson ailment commonly require greater regularly occurring levodopa doses (eg, each 2-3 hours) in addition to greater doses [63]. This phenomenon is not due to remedy tolerance or loss of efficacy of levodopa. As Parkinson sickness progresses, folks lose their long-duration response to dopaminergic medication, and their short-duration response decreases due to disease-related pathophysiologic changes in the brain. The talent additionally loses the capacity to store extra dopamine (whether produced internally or furnished through medication) for later use [64].

Various medicines are beneficial adjuncts to levodopa [65]. MAO-B inhibitors and dopamine agonists are dosed 1 to 3 instances every day (depending on drug, formulation) through out the ailment course, not like levodopa, which requires more frequent dosing over time. Catechol-O-methyl transferase inhibitors' and MAO-B inhibitors block enzymes that degrade dopamine, prolonging the advantages of levodopa. For persons with severe off intervals and delayed onset with subsequent dosing, subcutaneous apomorphine injection and inhaled levodopa 50 can be used to gain a quicker medicine response [66]. Subcutaneous apomorphine is self-administered by using an injection pen, and inhaled levodopa consists of an encapsulated powder administered orally with the aid of an inhaler. Each of these remedies can be used up to 5 instances daily [67]. Intermittent and non-stop apomorphine infusions are accessible outdoor the United States [68]. Dyskinesia are handled by using lowering dopaminergic medicines or adding amantadine. Immediate-release amantadine is used off label for dyskinesias, with two extended-release preparations approved by the FDA [68].

Conclusion:

Parkinson complaint is a neurodegenerative complaint that's clinically diagnosed grounded on its motor features, with non-motor symptoms being honored generally. The

Parkinson's Infection Establishment has assessed that the joined intermittent immediate and roundabout expenses of PD in the US is \$ 25 billion. The neurobiology of PD is multifactorial and there's lower success in the remedial paradigm applied for the complaint so far. Till date, characteristic rectification is the only means of applicable treatment for PD. Despite the fact that no neuroprotective remedies are yet available, many clinical and surgical remedies exist that can be utilized in specific stages through-out the direction of disease for symptomatic remedy of both motor and non-motor capabilities. Standard practitioners play a crucial role in recognizing the feasible signs and symptoms and signs and symptoms of PD and referring their sufferers to specialists with get right of entry to to the latest information and clinical skills in pharmacological, surgical and non pharmacological interventions. Different experimental fashions were stated to result in PD like signs and disturbed pathological situations related to PD. More studies and research are the want of time to interfere all of the feasible pathways related to PD pathology, which in flip should offer higher healing promise in future.

REFERENCE:

- [1] Borah, Anupom , et al. "Neuroprotective Effect of Ayurvedic Preparations and Natural Products on Parkinson's Disease." *Neuroprotective Natural Products: Clinical Aspects and Mode of Action*, 2017.
- [2] Cannas, A., M. Meloni , and F. Marrosu. "Suicide in Parkinson's Disease: An Open Question and a Complex and Poorly Explored Phenomenon." *Journal of Neurological Disorder*, Vol. 4, No. 273, 2016, p. 2.
- [3]Rajat Bhardwaj and Rahul Deshmukh (2018) Parkinson's Disease: An Insight into Mechanisms and Model Systems, *International Journal of Medical Research & Health Sciences*,2018,7(9):38-51.
- [4]Joseph Jankovic, Parkinson's disease: Etiopathogenesis and treatment, Jankovic J, Tan EK. *J Neurol Neurosurg Psychiatry*(2020);91:795–808. Doi:10.1136/jnnp-2019-322338.
- [5] Lola Cook, The commercial genetic testing Landscape for Parkinson's disease, *Parkinsonism And Related Disorders*, <https://doi.org/10.1016/j.parkreldis.2021.10.001>.
- [6]Philippe Rizek MD, Niraj Kumar MD DM, Mandar S. Jog MD (2016) An update on the diagnosis And treatment of Parkinson disease, *CMAJ*, November 1,188(16),2016, DOI:10.150/cmaj.151179.
- [7]Braak H, Del Tredici K, Rüb U, et al. Staging of brain pathology related to sporadic Parkinson's disease. *Neurobiol Aging* 2003; 24:197-211.
- [8]Dorsey ER, Constantinescu R, Thompson JP, et al. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030. *Neurology* 2007;68:384-6.
- [9]de Rijk MC, Tzourio C, Breteler MM, et al. Prevalence of parkinsonism and Parkinson's disease in Europe: the EUROPARKINSON Collaborative Study. European Community Concerted Action on the Epidemiology of Parkinson's disease. *J Neurol Neurosurg Psychiatry* 1997;62:10-5.

- [10])Thomas Fritsch, PhD, Parkinson Disease Research Update and Clinical Management, Association 0038-4348/0Y2000/105-650 CMC Activity of 2012 by The Southern Medical Association 0038-4348/0Y2000/105-650.
- [11] Prandovszky, Emese, et al. “The neurotropic parasite *Toxoplasma gondii* increases dopamine metabolism.” *PloS one*, Vol. 6, No. 9, 2011.
- [12] Bhattacharjee, Nivedita, et al. “L-DOPA treatment in MPTP-mouse model of Parkinson’s disease potentiates homocysteine accumulation in substantia nigra.” *Neuroscience Letters*, Vol. 628, 2016, pp. 225-29.
- [13] Kumar, Kushal, et al. “Therapeutic potential of GABAB receptor ligands in drug addiction, anxiety, depression and other CNS disorders.” *Pharmacology Biochemistry and Behavior*, Vol. 110, 2013, pp. 174-84.
- [14] Marras C, Lang A, van de Warrensburg BP, et al. Nomenclature of genetic movement disorders: recommendations of the International Parkinson and movement disorder Society Task force. *Mov Disord* 2016;31:436–57.
- [15] Deng H, Wang P, Jankovic J. The genetics of Parkinson disease. *Ageing Res Rev* 2018;42:72–85.
- [16] B. H. Wood, J. A. Bilclough, A. Bowron, and R. W. Walker “Incidence and prediction of falls in Parkinson’s disease: a prospective multidisciplinary study,” *Journal of Neurology Neurosurgery and Psychiatry*, vol. 72, no. 6, pp. 721–725, 2002.
- [17] R. M. Pickering, Y. A. M. Grimbergen, U. Rigney et al., “A meta-analysis of six prospective studies of falling in Parkinson’s disease,” *Movement Disorders*, vol. 22, no. 13, pp. 1892–1900, 2007.
- [18] Dorsey ER, Bloem BR. The Parkinson Pandemic—A call to action. *JAMA Neurol* 2018 ;;75:9–10. 1.
- [19] Dorsey ER, Elbaz A, Nichols E, et al. Global, regional, and national burden of Parkinson’s disease, 1990-2016: a systematic analysis for the global burden of disease study 2016. *Lancet Neurol* 2018;17:939–53.
- [20] Marras C, van de Warrenburg BP, et al. Nomenclature of genetic movement disorders: recommendations of the International Parkinson and movement disorder Society Task force. *Mov Disord* 2016;31:436–57.
- [21] O.-B. Tysnes, A. Storstein, Epidemiology of Parkinson’s disease, *J. Neural. Transm.* 124 (2017) 901–905, <https://doi.org/10.1007/s00702-017-1686-y>.
- [22] V. Skrahina, H. Gaber, E.-J. Vollstedt, T.M. Forster, T. Usnich, F. Curado, N. Brüggemann, J. Paul, X. Bogdanovic, S. Zülbahar, M. Olmedillas, S. Skobalj, N. Ameziane, P. Bauer, I. Csoti, N. Koleva-Alazeh, U. Grittner, A. Westenberger, M. Kasten, C. Beetz, C. Klein, A. Rolfs, ROPAD study group, the rostock international Parkinson’s disease (ROPAD) study: protocol and initial findings, *Mov. Disord.* 36 (2021) 1005–1010, <https://doi.org/10.1002/mds.28416>.
- [23] C.Y. Kim, R.N. Alcalay, Genetic forms of Parkinson’s disease, *Semin. Neurol.* 37 (2017) 135–146, <https://doi.org/10.1055/s-0037-1601567>.
- [24] X. Reed, S. Bandrés-Ciga, C. Blauwendraat, M.R. Cookson, The role of monogenic genes in idiopathic Parkinson’s disease, *Neurobiol. Dis.* 124 (2019) 230–239, <https://doi.org/10.1016/j.nbd.2018.11.012>.
- [25] A. Weissbach, C. Wittke, M. Kasten, C. Klein, Chapter seven - ‘atypical’ Parkinson’s disease – genetic, in: M. Stamelou, G.U. Hoglinger (Eds.), *International Review of Neurobiology*, Academic Press, 2019, pp. 207–235, <https://doi.org/10.1016/bs.irn.2019.10.011>.
- [26] C. Wittke, S. Petkovic, V. Dobricic, S. Schaake, G. Respondek, A. Weissbach, H. Madoev, J. Trinh, E.-J. Vollstedt, N. Kuhnke, K. Lohmann, M.D. Mahlow, C. Marras, I.R. König, M. Stamelou, V. Bonifati, C.M. Lill, M. Kasten, H.-J. Huppertz, G. Hoglinger, C. Klein, Genotype–Phenotype Relations for the Atypical Parkinsonism Genes: MDSGene Systematic Review, *Movement Disorders*. March 19 2021. <https://doi.org/10.1002/mds.28517...>
- [27] M.A. Nalls, C. Blauwendraat, C.L. Vallerga, K. Heilbron, S. Bandres-Ciga, D. Chang, et al., Identification of novel risk loci, causal insights, and heritable risk for Parkinson’s disease: a meta-analysis of genome-wide

association studies, *Lancet Neurol.* 18 (2019) 1091–1102, [https://doi.org/10.1016/S1474-4422\(19\)30320-5](https://doi.org/10.1016/S1474-4422(19)30320-5).

[28] S.A. Schneider, B. Hizli, R.N. Alcalay, Emerging targeted therapeutics for genetic subtypes of parkinsonism, *Neurotherapeutics* 17 (2020) 13781392, <https://doi.org/10.1007/s13311-020-00920-8>.

[29] W.S. Rubinstein, D.R. Maglott, J.M. Lee, B.L. Kattman, A.J. Malheiro, M. Ovetsky, V. Hem, V. Gorelenkov, G. Song, C. Wallin, N. Husain, S. Chitipiralla, K.S. Katz, D. Hoffman, W. Jang, M. Johnson, F. Karmanov, A. Ukrainchik, M. Denisenko, C. Fomous, K. Hudson, J.M. Ostell, The NIH genetic testing registry: a new, centralized database of genetic tests to enable access to comprehensive information and improve transparency, *Nucleic Acids Res.* 41 (2013) D925–D935, <https://doi.org/10.1093/nar/gks1173>.

[30] Ascherio A, Schwarzschild MA. The epidemiology of Parkinson's disease: risk factors and prevention. *Lancet Neurol* 2016;15:1257–72.

[31] Simon DK, Tanner CM, Brundin P. Parkinson disease epidemiology, pathology, genetics, and pathophysiology. *Clin Geriatr Med* 2020;36:1–12.

[32] González-Casacuberta I, Juárez-Flores DL, Morén C, et al. Bioenergetics and autophagic imbalance in patients-derived cell models of Parkinson disease supports systemic dysfunction in neurodegeneration. *Front Neurosci* 2019;13:894. Pohl C, Dikic I. Cellular quality control by the ubiquitin-proteasome system and autophagy. *Science* 2019;366:818–22.

[33] Savica R, Turcano P, Bower JH, et al. Survival and progression in synucleinopathy phenotypes with parkinsonism: a population-based study. *Mayo Clin Proc* 2019;94:1825–31.

[34] Prange S, Danaila T, Laurencin C, et al. Age and time course of long-term motor and nonmotor complications in Parkinson disease. *Neurology* 2019;92:e148–60.

[35] De Pablo-Fernández E, Lees AJ, Holton JL, et al. Prognosis and neuropathological correlation of clinical subtypes of Parkinson disease. *JAMA Neurol* 2019;76:470–9. <https://web.whatsapp.com/>

[36] Das, S. K., et al. "Epidemiology of Parkinson disease in the city of Kolkata, India A community-based study." *Neurology*, Vol. 75, No. 15, 2010, pp.1362-69. <chrome-extension://mhjfbmdgcfjbbpaeojofohoefgihjai/index.html>.

[37] Fahn S. The 200-year journey of Parkinson disease: reflecting on the past and looking towards the future. *Parkinsonism Relat Disord* 2018;46:S1–5.

[38] Langston JW. The MPTP story. *J Parkinson's Dis* 2017;7:S11–19.

[39] Polymeropoulos MH et al. Mutation in the -synuclein gene identified in families with Parkinson's disease. *Science* 1997;276:2045–7.

[40] Chan SL, Tan E-K. Targeting LRRK2 in Parkinson's disease: an update on recent developments. *Expert Opin Ther Targets* 2017;21:601–10.

[41] Montauk S, Trenchant C, Drouot N, et al. Assessment of a targeted gene panel for identification of genes associated with movement disorders. *JAMA Neurol* 2018;75:1234–45.

[42] Alexander GE, DeLong MR, Strick PL. Parallel organization of functionally segregated circuits linking basal ganglia and cortex. *Annu Rev Neurosci* 1986;9:357-81.

[43] Braak H, Del Tredici K, Rüb U, et al. Staging of brain pathology related to sporadic Parkinson's disease. *Neurobiol Aging* 2003; 24:197-211.

[44] Jankovic J. Progression of Parkinson disease: Are we making progress in charting the course? *Arch Neurol* 2005;62:351-2.

[45] Kim HJ, Jeon BS, Paek SH. Nonmotor symptoms and subthalamic deep brain stimulation in Parkinson's disease. *J Mov Disord* 2015;8:83-91.

[46] Hemmerle AM, Herman JP, Seroogy KB. Stress, depression and Parkinson's disease. *Exp Neurol* 2012;233:79-86.

[47] Pathophysiology of Parkinson's Disease by https://en.m.wikipedia.org/wiki/Pathophysiology_of_Parkinson's_disease.

[48] R.S.Satoskar, Nirmala N.Rage, S.D.Bhandarkar, 2015 *Pharmacology and Pharmacotherapeutics* 24th Edition. <https://web.whatsapp.com/>

- [49]Kumar, Push Pender, et al. “Role of neurosteroids in experimental 3-nitropropionic acid induced neurotoxicity in rats.” *European Journal of Pharmacology*, Vol. 723, 2014, pp. 38-45.
- [50]Chase, Thomas N., and Justin D. Oh. “Striatal dopamine-and glutamate-mediated dysregulation in experimental parkinsonism.” *Trends in Neurosciences*, Vol. 23, 2000, pp. 86-91.
- [51]Obeso, José A., et al. “Pathophysiology of the basal ganglia in Parkinson’s disease.” *Trends in Neurosciences*, Vol. 23, 2000, pp. 8-19.
- [52] Rodriguez, M. C., J. A. Obeso, and C. Warren Olanow. “Subthalamic nucleus - mediated excitotoxicity in Parkinson’s disease: a target for neuroprotection.” *Annals of Neurology*, Vol. 44, No. 1, 1998, pp. 175-88.
- [53] Hikosaka, Okihide. “Basal ganglia-possible role in motor coordination and learning.” *Current Opinion in Neurobiology*, Vol. 1, No. 4, 1991, pp.638-43.
- [54] <https://www.mayoclinic.org/diseases-conditions/parkinsons-disease/symptoms-causes/syc-20376055>.
- [55] Trackwalker C, Kuoppamäki M, Vahteristo M, et al. Increased dose of carbidopa with levodopa and entacapone improves “off” time in a randomized trial. *Neurology* 2019;92:e1487–96.
- [56] Mehanna R, Jankovic J. Young-Onset Parkinson’s disease: its unique features and their impact on quality of life. *Parkinsonism Relat Disord* 2019;65:39–48.
- [57] Savitr D, Jankovic J. Targeting α -Synuclein in Parkinson’s Disease: Progress Towards the Development of Disease-Modifying Therapeutics. *Drugs* 2019;79:797–810.
- [58]Espay AJ, Hauser RA, Armstrong MJ. The narrowing path for nilotinib and other potential disease-modifying therapies for Parkinson disease. *JAMA Neurol* 2019. doi:10.1001/jamaneurol.2019.3983. [Epub ahead of print: 16 Dec 2019].
- [59]Ding X, Ren F. Leucine-rich repeat kinase 2 inhibitors: a patent review(2014-present). *Expert Opin Ther Pat* 2020:1–12.
- [60]Mullin S, Smith L, Lee K, et al. Amroxolol for the treatment of patients with Parkinson disease with and without glucocerebrosidase gene mutations. *JAMA Neurol* 2020;77:427.
- [61]Pahwa R, Lyons KE, Hauser RA, et al. Randomized trial of IPX066, carbidopa/levodopa extended release, in early Parkinson’s disease. *Parkinsonism Relat Disord* 2014;20:142–8.
- [62]Hauser RA, Hsu A, Kell S, et al. Extended-Release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson’s disease and motor fluctuations: a phase 3 randomised, double-blind trial. *Lancet Neurol* 2013;12:346–56.
- [63] Lang AE, Rodriguez RL, Boyd JT, et al. Integrated safety of levodopa-carbidopa intestinal gel from prospective clinical trials. *Mov Disord* 2016;31:538–46.
- [64]Merola A, Zibetti M, Angrisano S, et al. Comparison of subthalamic nucleus deep brain stimulation and Duodopa in the treatment of advanced Parkinson’s disease. *Mov Disord* 2011;26:664–70.
- [65]Rosebraugh M, Kym P, Liu W, et al. A Novel Levodopa/Carbidopa Prodrug (ABBV- 951) 24-Hour Continuous Subcutaneous Infusion Treatment for Parkinson’s Disease. *Neurology* 2019;92.
- [66]LeWitt PA, Hauser RA, Pahwa R, et al. Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson’s disease: a randomised, double-blind, placebo-controlled phase 3 trial. *The Lancet Neurology* 2019;18:145–54.
- [67]Vijiaratnam N, Foltynie T. Therapeutic strategies to treat or prevent off episodes in adults with Parkinson’s disease. *Drugs* 2020;80:775–96.
- [68]Pessoa RR, Moro A, Munhoz RP, et al. Apomorphine in the treatment of Parkinson’s disease: a review. *ArqNeuropsiquiatr* 2018;76::840–848.